Article and Video CATEGORIES

Cancer Journey

Search By

Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?
GRACE Videos and Articles



Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.


Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.



Dr. West:  Here at the World Conference on Lung Cancer, like ASCO, immunotherapy was a really hot topic — not a lot of new data here, but still a lot of on going controversies, and one of them, in fact, a featured question at a symposium that I hosted on current debates, is whether these agents are clearly clinically distinct, or largely interchangeable. Do you have a sense of that based on the data, your own impressions, right now?

Dr. Horn:  So, the response rates seem similar — it’s hard to gauge between agents because they seem to have different cut points, different assays. I think that there are going to be some differences between a PD-1 and the PD-L1 agents, and some of the clinical experience that I’ve had at our institution is that, PD-1 patients, for the most part, who have come off therapy, I’ve had less patients who have progressed at a later point, and I’ve actually treated one patient who came off a PD-L1 inhibitor, after progression, with retreatment with a PD-1 inhibitor, who then responded. So, I think that there is interesting science that we need to sort out between the way these different drugs act, but it may turn out that there are some subtle differences in the efficacy between the PD-L1 versus the PD-1 inhibitors.

Dr. West:  I think these are the kinds of questions we’re wrestling with — for instance, as we get other drugs on the market, will it make sense to treat with a PD-L1 inhibitor after a PD-1 inhibitor, or vice versa, or is there a huge amount of cross-resistance, toxicity differences — pneumonitis really a significant issue with PD-1 but maybe not an issue with PD-L1. What are your thoughts Ben?

Dr. Solomon:  Yeah, I think it’s still early days in terms of resolving those questions. I think most of the data, like Leora was describing, are anecdotal now. At a clinical level, response rates and toxicity are broadly similar across the classes. I think there may be some subtle differences that are emerging — I mean there are different targets, PD-1 is a receptor which is on the surface of lymphocytes, whereas PD-L1 is a ligand, which is expressed on the surface of tumor cells, and the ligand can interact with different receptors, and the receptor can be activated by different ligands. So, it wouldn’t surprise me, over time, whether some differences emerge.

Next Previous link

Previous PostNext Post

Related Content

Blood Cancer OncTalk
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridevi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:
View the full Targeted Therapies in Lung Cancer Patient forum from 2023 in YouTube and embedded here! 

Forum Discussions

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,


As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

Hi Amber, Welcome to Grace. …
By JanineT GRACE … on
Could you
By Maeve785 on
It sounds like you’re…
By Dr West on
Thank you Janine
By blaze100 on